CSIMarket
 


Tscan Therapeutics Inc   (TCRX)
Other Ticker:  
 

Tscan Therapeutics Inc 's Tangible Leverage Ratio

TCRX's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -4.27%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 0.39 is above the company's typical Tangible Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2023, 72 other companies have achieved lower Tangible Leverage Ratio than Tscan Therapeutics Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 564 to 834 .

Explain Tangible Leverage Ratio?
What is TCRX Market Share?
What are TCRX´s Total Liabilities?


TCRX Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change 44.83 % 44.78 % -46.45 % -38.15 % -32.98 %
Y / Y Total Liabilities Change 48.69 % 340.04 % 135.72 % 101.84 % 80.18 %
Tangible Leverage Ratio MRQ 0.39 0.36 0.51 0.43 0.38
TCRX's Total Ranking # 834 # 564 # 1058 # 775 # 927
Seq. Tangible Equity Change -11.36 % 144.31 % -21.54 % -14.76 % -11.39 %
Seq. Total Liabilities Change -4.27 % 71.82 % -7.48 % -2.29 % 183.29 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 73
Healthcare Sector # 385
Overall Market # 834


Tangible Leverage Ratio Statistics
High Average Low
0.51 0.29 0.12
(Mar 31 2023)   (Mar 31 2022)




Financial Statements
Tscan Therapeutics Inc 's Tangible Equity $ 169 Millions Visit TCRX's Balance sheet
Tscan Therapeutics Inc 's Total Liabilities $ 65 Millions Visit TCRX's Balance sheet
Source of TCRX's Sales Visit TCRX's Sales by Geography


Cumulative Tscan Therapeutics Inc 's Tangible Leverage Ratio

TCRX's Tangible Leverage Ratio for the trailling 12 Months

TCRX Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth 44.83 % 44.78 % -46.45 % -38.15 % -32.98 %
Y / Y Total Liabilities TTM Growth 48.69 % 340.04 % 135.72 % 101.84 % 80.18 %
Tangible Leverage Ratio TTM 0.4 0.4 0.33 0.24 0.18
Total Ranking TTM # 8 # 48 # 5 # 382 # 532
Seq. Tangible Equity TTM Growth -11.36 % 144.31 % -21.54 % -14.76 % -11.39 %
Seq. Total Liabilities TTM Growth -4.27 % 71.82 % -7.48 % -2.29 % 183.29 %


On the trailing twelve months basis Due to repayements of liabilities of -4.27% Tscan Therapeutics Inc has not changed Tangible Leverage Ratio in the 12 months ending in III Quarter 2023 to 0.4, below the company's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry TCRX recorded the lowest Tangible Leverage Ratio. While Tangible Leverage Ratio total ranking has improved so far to 8, from total ranking in previous 12 month period at 48.

Explain Tangible Leverage Ratio?
What is TCRX Market Share?
What are TCRX´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 1
Within the Market # 8


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.83 0.53 0.17
(Sep 30 2023)   (Jun 30 2022)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Xtant Medical Holdings Inc   0.99 $ 37.322  Millions$ 37.675  Millions
Inmune Bio Inc   0.92 $ 25.155  Millions$ 27.419  Millions
Sab Biotherapeutics Inc   0.86 $ 13.080  Millions$ 15.256  Millions
Century Therapeutics inc   0.81 $ 178.321  Millions$ 219.230  Millions
Kodiak Sciences Inc   0.81 $ 245.235  Millions$ 302.417  Millions
Avalon Globocare Corp   0.78 $ 13.145  Millions$ 16.823  Millions
Bluebird Bio Inc   0.75 $ 159.049  Millions$ 211.522  Millions
Regenxbio Inc   0.75 $ 270.686  Millions$ 363.100  Millions
Gritstone Bio Inc   0.73 $ 53.805  Millions$ 73.982  Millions
Ginkgo Bioworks Holdings Inc   0.71 $ 773.709  Millions$ 1,094.458  Millions
Repligen Corp  0.67 $ 522.257  Millions$ 775.576  Millions
Beam Therapeutics Inc   0.66 $ 511.593  Millions$ 778.941  Millions
Sangamo Therapeutics Inc   0.63 $ 84.775  Millions$ 134.922  Millions
Coeptis Therapeutics Holdings Inc   0.63 $ 2.752  Millions$ 4.393  Millions
Zura Bio Limited  0.62 $ 39.837  Millions$ 64.755  Millions
Elevation Oncology inc   0.60 $ 37.559  Millions$ 62.416  Millions
Senti Biosciences Inc   0.59 $ 48.830  Millions$ 82.936  Millions
Vericel Corporation  0.58 $ 113.745  Millions$ 197.349  Millions
Aligos Therapeutics Inc   0.57 $ 31.031  Millions$ 54.821  Millions
Recursion Pharmaceuticals Inc   0.56 $ 192.858  Millions$ 345.758  Millions
Vaxart Inc   0.55 $ 34.121  Millions$ 62.541  Millions
C4 Therapeutics Inc   0.54 $ 116.989  Millions$ 216.024  Millions
Miromatrix Medical inc   0.51 $ 7.879  Millions$ 15.542  Millions
Seagen Inc   0.46 $ 954.716  Millions$ 2,055.495  Millions
Moderna Inc   0.45 $ 5,995.000  Millions$ 13,455.000  Millions
Neurocrine Biosciences Inc   0.43 $ 846.100  Millions$ 1,967.200  Millions
Scholar Rock Holding Corp  0.41 $ 69.489  Millions$ 167.665  Millions
Instil Bio Inc   0.40 $ 94.426  Millions$ 234.024  Millions
Editas Medicine Inc   0.40 $ 144.188  Millions$ 360.462  Millions
Tscan Therapeutics Inc   0.39 $ 65.380  Millions$ 168.961  Millions

Date modified: 2023-11-12T12:47:44+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com